Urs Ochsner

USPTO Granted Patents = 12 (Patent Applications = 3)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 3.3

ph-index = 4

Forward Citations = 41(Granted Patents)

Location History:

Denver, CO (US) (2014 - 2020)
Boulder, CO (US) (2018 - 2023)

Company Filing History:

10 out of 75

Somalogic, Incorporated

Somalogic Operating Co., Inc.

where one patent can have more than one assignee

Years Active: 2014-2023

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11655225 - Antimycobacterial heterocyclic amides (2023-05-23),

2. 11535852 - Nucleic acid compounds for binding growth differentiation factor 11 (2022-12-27),

3. 10808251 - Nucleic acid compounds for binding growth differentiation factor 11 (2020-10-20),

4. 10538771 - Compositions and methods for detecting microorganisms (2020-01-21),

5. 10526663 - Method of detecting a microorganism in a sample by a fluorescence based detection method (2020-01-07),

6. 10408847 - Tuberculosis biomarkers and uses thereof (2019-09-10),

7. 10392621 - Multiaptamer target detection (2019-08-27),

8. 10370669 - Nucleic acid compounds for binding growth differentiation factor 8 (2019-08-06),

9. 10093933 - Compositions and methods for detecting microorganisms (2018-10-09),

10. 9926566 - Multiaptamer target detection (2018-03-27),

11. 9081010 - Aptamers for clostridium difficile diagnostics (2015-07-14),

12. 8895241 - [object Object] (2014-11-25),

Title: The Innovative Mind of Urs Ochsner

Introduction

Urs Ochsner, an accomplished inventor residing in Boulder, Colorado, has made significant contributions to the field of biochemistry and pharmaceuticals. With a remarkable portfolio of 12 patents to his name, Ochsner is recognized for his innovative approaches to tackling health-related challenges through unique chemical compounds.

Latest Patents

Two of Urs Ochsner's latest patents showcase his focus on antimicrobial and biopharmaceutical advancements. The first, titled "Antimycobacterial Heterocyclic Amides," introduces novel heterocyclic amide compounds that exhibit promising antimycobacterial activity. This invention also outlines their potential use as pharmaceutical compositions and the methodologies for their production. The second patent, related to "Nucleic Acid Compounds for Binding Growth Differentiation Factor 11," features aptamers that bind to the GDF11 protein. This innovation includes compositions that incorporate a GDF11 binding aptamer alongside the GDF11 protein, as well as methods for fabrication and application.

Career Highlights

Throughout his career, Urs Ochsner has been associated with notable companies such as Somalogic and Merck Patent GmbH. His work at these organizations has led to impactful research and developments in the field of life sciences, specifically targeting therapeutic solutions through his innovative inventions.

Collaborations

Urs Ochsner has collaborated with reputable professionals in his field, including Nebojsa Janjic and Louis S. Green. These partnerships have contributed to the advancement of his research efforts and the successful realization of his patented innovations.

Conclusion

Urs Ochsner continues to be a driving force in the realm of innovation, with his patents reflecting a commitment to improving health outcomes through science. His work not only demonstrates his ingenuity as an inventor but also highlights the importance of collaboration in developing effective solutions for contemporary medical challenges.

This text is generated by artificial intelligence and may not be accurate.